Preveceutical Medical Inc C.PREV

Alternate Symbol(s): PRVCF

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity. Its Nature Identical peptides for treatment of various ailments. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

CSE:PREV - Post by User

Preveceutical Medical Inc

Bullboard Posts

Comment by Cashmeoussideon Mar 26, 2019 8:50am

32 Views

Post# 29535547

RE:RE:PreveCeutical Announces Default Judgment

You’ve been here for ages and have been caught before trying to cloud judgment, not provide a reality check. You’re still playing the red herring game and trying to distract from the implications of this news to put a negative spin on the company’s prospects. It’ll work on weak hands.

CanadaCoin wrote: PREV filed claim against 15 Defendents.

Today, PREV was awarded a default judgement against 2 of the 15 defendents. Is it possible that these are the only two that bailed and did not submit a defense? :)

And whether these two bailed or not, do you honestly think PREV will collect anything on that default judgement? :)

Please excuse me, but I'm just trying to provide a reality check.

medmaryJ wrote:

https://ceo.ca/@newsfile/preveceutical-announces-default-judgment-against-essos

"The amount of damages and costs to be awarded to the Company and against Essos and Detona remain to be assessed by the court. The Company is continuing to pursue its claims against the other Defendants in the Action."